Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan, To U.S. Food And Drug Administration

iling for ABP 798 Supported by Two Comparative Clinical Studies THOUSAND OAKS, Calif., Dec. 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a

Benzinga · 12/19/2019 21:45

iling for ABP 798 Supported by Two Comparative Clinical Studies

THOUSAND OAKS, Calif., Dec. 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.